Dia-B Tech

Dia-B Tech is a South Korean biotechnology company specializing in the development of oral delivery systems for peptide and protein-based therapeutics. The company's primary focus is on metabolic disorders, specifically diabetes, where it aims to replace traditional subcutaneous injections with patient-friendly oral formulations. Its lead program, DB-001, is an oral insulin candidate designed to improve patient quality of life and treatment adherence by maintaining stable glycemic control without the need for needles. Dia-B Tech utilizes a proprietary platform technology that protects biologics from degradation in the gastrointestinal tract while facilitating efficient absorption into the bloodstream.